

Tun-Jun Tsai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3193378/publications.pdf>

Version: 2024-02-01

130
papers

5,564
citations

87401

40
h-index

104191

69
g-index

130
all docs

130
docs citations

130
times ranked

6428
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations between urinary cysteine-rich protein 61 excretion and kidney function decline in outpatients with chronic kidney disease: a prospective cohort study in Taiwan. <i>BMJ Open</i> , 2021, 11, e051165.	0.8	1
2	Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update. <i>Journal of Biomedical Science</i> , 2017, 24, 84.	2.6	22
3	Autonomic dysfunction in chronic kidney disease: An old problem in a new era. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 687-688.	0.8	16
4	A tribute to Professor Wan-Yu Chen. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 791-792.	0.8	0
5	Web-based pulse analysis system for detection of acute kidney injury. , 2015, , .		0
6	Multidisciplinary Care Program for Advanced Chronic Kidney Disease: Reduces Renal Replacement and Medical Costs. <i>American Journal of Medicine</i> , 2015, 128, 68-76.	0.6	88
7	Gender effect on quality of life in hemodialysis patients: response to Einollahi and Motalebi. <i>Journal of Nephrology</i> , 2014, 27, 593-593.	0.9	0
8	Lineage Tracing Reveals Distinctive Fates for Mesothelial Cells and Submesothelial Fibroblasts during Peritoneal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2847-2858.	3.0	117
9	Blockade of cysteine-rich protein 61 attenuates renal inflammation and fibrosis after ischemic kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F581-F592.	1.3	34
10	Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 219-226.	0.8	283
11	Transforming Growth Factor β 2-1 Stimulates Profibrotic Epithelial Signaling to Activate Pericyte-Myofibroblast Transition in Obstructive Kidney Fibrosis. <i>American Journal of Pathology</i> , 2013, 182, 118-131.	1.9	206
12	Renovascular disease in Taiwan: A long-term nationwide population study. <i>International Journal of Cardiology</i> , 2013, 168, 541-542.	0.8	2
13	Lifetime Costs for Peritoneal Dialysis and Hemodialysis in Patients in Taiwan. <i>Peritoneal Dialysis International</i> , 2013, 33, 671-678.	1.1	34
14	Cysteine-Rich Protein 61 Plays a Proinflammatory Role in Obstructive Kidney Fibrosis. <i>PLoS ONE</i> , 2013, 8, e56481.	1.1	27
15	Women on hemodialysis have lower self-reported health-related quality of life scores but better survival than men. <i>Journal of Nephrology</i> , 2013, 26, 366-374.	0.9	14
16	Clinical Outcomes and Predictors for ESRD and Mortality in Primary GN. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1401-1408.	2.2	61
17	Treating baclofen overdose by hemodialysis. <i>American Journal of Emergency Medicine</i> , 2012, 30, 1654.e5-1654.e7.	0.7	30
18	Effect of Diuretic Use on 30-Day Postdialysis Mortality in Critically Ill Patients Receiving Acute Dialysis. <i>PLoS ONE</i> , 2012, 7, e30836.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Fibrin-Induced Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells as a Mechanism of Peritoneal Fibrosis: Effects of Pentoxifylline. <i>PLoS ONE</i> , 2012, 7, e44765.	1.1	24
20	Safety Issues of Long-Term Glucose Load in Patients on Peritoneal Dialysis—A 7-Year Cohort Study. <i>PLoS ONE</i> , 2012, 7, e30337.	1.1	42
21	Impact of timing of renal replacement therapy initiation on outcome of septic acute kidney injury. <i>Critical Care</i> , 2011, 15, R134.	2.5	87
22	Pleiotropic Effects of Sevelamer Beyond Phosphate Binding in End-Stage Renal Disease Patients. <i>Clinical Drug Investigation</i> , 2011, 31, 257-267.	1.1	19
23	Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. <i>Kidney International</i> , 2011, 80, 1222-1230.	2.6	163
24	Targeting Endothelium-Pericyte Cross Talk by Inhibiting VEGF Receptor Signaling Attenuates Kidney Microvascular Rarefaction and Fibrosis. <i>American Journal of Pathology</i> , 2011, 178, 911-923.	1.9	224
25	Combining body mass index and serum potassium to urine potassium clearance ratio is an alternative method to predict primary aldosteronism. <i>Clinica Chimica Acta</i> , 2011, 412, 1637-1642.	0.5	4
26	Primary aldosteronism. <i>Journal of Hypertension</i> , 2011, 29, 1778-1786.	0.3	81
27	Comparison of self-reported health-related quality of life between Taiwan hemodialysis and peritoneal dialysis patients: a multi-center collaborative study. <i>Quality of Life Research</i> , 2011, 20, 399-405.	1.5	18
28	Tamoxifen Downregulates Connective Tissue Growth Factor to Ameliorate Peritoneal Fibrosis. <i>Blood Purification</i> , 2011, 31, 252-258.	0.9	23
29	Nasal Carriage of Methicillin-resistant <i>Staphylococcus aureus</i> Is Associated with Higher All-Cause Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 167-174.	2.2	49
30	Outcomes following Dialysis for Acute Kidney Injury among Different Stages of Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 34, 95-103.	1.4	5
31	Associations of metabolic syndrome and its components with cardiovascular outcomes among non-diabetic patients undergoing maintenance peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 4047-4054.	0.4	33
32	Platelet-derived growth factor receptor signaling activates pericyte—myofibroblast transition in obstructive and post-ischemic kidney fibrosis. <i>Kidney International</i> , 2011, 80, 1170-1181.	2.6	273
33	Cognitive-behavioral therapy for sleep disturbance decreases inflammatory cytokines and oxidative stress in hemodialysis patients. <i>Kidney International</i> , 2011, 80, 415-422.	2.6	108
34	Association of Low Serum Fetuin A Levels With Poor Arteriovenous Access Patency in Patients Undergoing Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2010, 56, 720-727.	2.1	19
35	Risk Factors for High Dialysate Glucose use in PD Patients—A Retrospective 5-Year Cohort Study. <i>Peritoneal Dialysis International</i> , 2010, 30, 448-455.	1.1	19
36	Mini-Laparotomy Implantation of Peritoneal Dialysis Catheters: Outcome and Rescue. <i>Peritoneal Dialysis International</i> , 2010, 30, 513-518.	1.1	40

#	ARTICLE	IF	CITATIONS
37	Are Both Psychological and Physical Dimensions in Health-Related Quality of Life Associated with Mortality in Hemodialysis Patients: A 7-Year Taiwan Cohort Study. <i>Blood Purification</i> , 2010, 30, 98-105.	0.9	17
38	Ioxitalamate Induces Renal Tubular Apoptosis via Activation of Renal Efferent Nerve-Mediated Adrenergic Signaling, Renin Activity, and Reactive Oxygen Species Production in Rats. <i>Toxicological Sciences</i> , 2010, 114, 149-158.	1.4	16
39	Maintenance haemodialysis and delayed administration of appropriate antibiotics increase 30-day mortality among patients with non-hospital-acquired methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 511-512.	1.1	4
40	Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 663-672.	0.8	11
41	Life expectancy, expected years of life lost and survival of hemodialysis and peritoneal dialysis patients. <i>Journal of Nephrology</i> , 2010, 23, 677-82.	0.9	21
42	Seven-Year Follow-Up of Peritoneal Dialysis Patients in Taiwan. <i>Peritoneal Dialysis International</i> , 2009, 29, 450-457.	1.1	18
43	Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients. <i>European Journal of Endocrinology</i> , 2009, 160, 777-783.	1.9	42
44	N-Acetylcysteine-Mediated Antioxidation Prevents Hyperglycemia-Induced Apoptosis and Collagen Synthesis in Rat Mesangial Cells. <i>American Journal of Nephrology</i> , 2009, 29, 192-202.	1.4	12
45	Intraperitoneal Vascular Endothelial Growth Factor C Level Is Related to Peritoneal Dialysis Ultrafiltration. <i>Blood Purification</i> , 2009, 28, 69-74.	0.9	8
46	Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2909-2914.	0.4	122
47	Pentoxifylline Inhibits Transforming Growth Factor-Beta Signaling and Renal Fibrosis in Experimental Crescentic Glomerulonephritis in Rats. <i>American Journal of Nephrology</i> , 2009, 29, 43-53.	1.4	37
48	Comparison of residual renal function in patients undergoing twice-a-week versus three-times-a-week haemodialysis. <i>Nephrology</i> , 2009, 14, 59-64.	0.7	105
49	The aggressiveness of urinary tract urothelial carcinoma increases with the severity of chronic kidney disease. <i>BJU International</i> , 2009, 104, 1471-1474.	1.3	23
50	Economic, Social, and Psychological Factors Associated With Health-Related Quality of Life of Chronic Hemodialysis Patients in Northern Taiwan: A Multicenter Study. <i>Artificial Organs</i> , 2009, 33, 61-68.	1.0	60
51	Correlations Between Spiritual Beliefs and Health-Related Quality of Life of Chronic Hemodialysis Patients in Taiwan. <i>Artificial Organs</i> , 2009, 33, 576-579.	1.0	16
52	The 90-day mortality and the subsequent renal recovery in critically ill surgical patients requiring acute renal replacement therapy. <i>American Journal of Surgery</i> , 2009, 198, 325-332.	0.9	78
53	Hyperuricemia Associated With Rapid Renal Function Decline in Elderly Taiwanese Subjects. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 921-928.	0.8	19
54	Seven-year follow-up of peritoneal dialysis patients in Taiwan. <i>Peritoneal Dialysis International</i> , 2009, 29, 450-7.	1.1	9

#	ARTICLE	IF	CITATIONS
55	Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment. <i>Nephrology</i> , 2008, 13, 198-203.	0.7	4
56	Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Peritoneal Dialysis: A Pilot Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2008, 52, 314-323.	2.1	89
57	Effect of Pentoxifylline in Addition to Losartan on Proteinuria and GFR in CKD: A 12-Month Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2008, 52, 464-474.	2.1	325
58	Initial Glucose Load Predicts Technique Survival in Patients on Chronic Peritoneal Dialysis. <i>American Journal of Nephrology</i> , 2008, 28, 765-771.	1.4	31
59	Outcomes of Stage 3–5 Chronic Kidney Disease before End-Stage Renal Disease at a Single Center in Taiwan. <i>Nephron Clinical Practice</i> , 2008, 109, c109-c118.	2.3	58
60	Impact of Spiritual and Religious Activity on Quality of Sleep in Hemodialysis Patients. <i>Blood Purification</i> , 2008, 26, 221-225.	0.9	12
61	Higher systemic inflammation is associated with poorer sleep quality in stable haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 247-251.	0.4	82
62	Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3831-3840.	0.4	22
63	Lercanidipine-Induced Chyloperitoneum in Patients on Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2008, 28, 632-636.	1.1	17
64	Predictors of Faster Decline of Residual Renal Function in Taiwanese Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2008, 28, 191-195.	1.1	62
65	Lysophosphatidic Acid and Renal Fibrosis. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2008, 2, 204-210.	0.7	0
66	Primary biliary cirrhosis associated with minimal change disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 966-967.	0.4	0
67	The association of higher depressive symptoms and sexual dysfunction in male haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 857-861.	0.4	59
68	Higher plasma interleukin-18 levels associated with poor quality of sleep in peritoneal dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3606-3609.	0.4	32
69	Peritoneal thickening is not inevitable in long-term peritoneal dialysis and is associated with peritoneal transport characteristics: a two-centre sonographic study. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1005-1010.	0.4	9
70	Sexual Dysfunction in Peritoneal Dialysis Patients. <i>American Journal of Nephrology</i> , 2007, 27, 615-621.	1.4	26
71	<i>In Vitro</i> Study of Peritoneal Fibrosis. <i>Peritoneal Dialysis International</i> , 2007, 27, 72-75.	1.1	5
72	Factors associated with metabolic acidosis in patients receiving parenteral nutrition. <i>Nephrology</i> , 2007, 12, 3-7.	0.7	17

#	ARTICLE	IF	CITATIONS
73	Bradykinin enhances reactive oxygen species generation, mitochondrial injury, and cell death induced by ATP depletion—A role of the phospholipase C α 2+ pathway. <i>Free Radical Biology and Medicine</i> , 2007, 43, 702-710.	1.3	11
74	Impact of Near-Death Experiences on Dialysis Patients: A Multicenter Collaborative Study. <i>American Journal of Kidney Diseases</i> , 2007, 50, 124-132.e2.	2.1	28
75	Poor Renal Outcome of Antineutrophil Cytoplasmic Antibody Negative Pauci-immune Glomerulonephritis in Taiwanese. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 804-812.	0.8	33
76	Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. <i>Kidney International</i> , 2006, 69, 1410-1415.	2.6	66
77	Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. <i>Free Radical Biology and Medicine</i> , 2006, 41, 1304-1314.	1.3	43
78	Peritoneal Permeability in Patients with Encapsulating Peritoneal Sclerosis. <i>American Journal of Kidney Diseases</i> , 2006, 48, 875.	2.1	1
79	Plasma Interleukin-18 Levels in Hemodialysis Patients: Increased by Dialysis Process and Association with Interleukin-6 and Tumor Necrotic Factor- α . <i>Blood Purification</i> , 2006, 24, 174-179.	0.9	12
80	Diltiazem suppresses collagen synthesis and IL-1 β -induced TGF- β 1 production on human peritoneal mesothelial cells. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1340-1347.	0.4	19
81	Sexual dysfunction in female hemodialysis patients: A multicenter study. <i>Kidney International</i> , 2005, 68, 760-765.	2.6	74
82	YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1—Independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. <i>European Journal of Pharmacology</i> , 2005, 517, 1-10.	1.7	17
83	Plasma Interleukin-18 Levels in Chronic Renal Failure and Continuous Ambulatory Peritoneal Dialysis. <i>Blood Purification</i> , 2005, 23, 144-148.	0.9	28
84	Pentoxifylline Attenuates Tubulointerstitial Fibrosis by Blocking Smad3/4-Activated Transcription and Profibrogenic Effects of Connective Tissue Growth Factor. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2702-2713.	3.0	142
85	Low-Density Lipoprotein Cholesterol: Association with Mortality and Hospitalization in Hemodialysis Patients. <i>Blood Purification</i> , 2005, 23, 134-140.	0.9	32
86	Peritoneal Fibrosing Syndrome: Pathogenetic Mechanism and Current Therapeutic Strategies. <i>Journal of the Chinese Medical Association</i> , 2005, 68, 401-405.	0.6	7
87	The Renoprotective Potential of Pentoxifylline in Chronic Kidney Disease. <i>Journal of the Chinese Medical Association</i> , 2005, 68, 99-105.	0.6	19
88	Pentoxifylline suppresses renal tumour necrosis factor- α and ameliorates experimental crescentic glomerulonephritis in rats. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1106-1115.	0.4	51
89	Dual Regulation of Tumor Necrosis Factor- α -Induced CCL2/Monocyte Chemoattractant Protein-1 Expression in Vascular Smooth Muscle Cells by Nuclear Factor- κ B and Activator Protein-1: Modulation by Type III Phosphodiesterase Inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 978-986.	1.3	62
90	Health-Related Quality of Life of Hemodialysis Patients in Taiwan: A Multicenter Study. <i>Blood Purification</i> , 2004, 22, 490-498.	0.9	55

#	ARTICLE	IF	CITATIONS
91	Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2810-2815.	0.4	40
92	Hemorrhagic Stroke in Chronic Dialysis Patients. <i>Renal Failure</i> , 2004, 26, 165-170.	0.8	10
93	Review Article. Pentoxifylline: A potential therapy for chronic kidney disease. <i>Nephrology</i> , 2004, 9, 198-204.	0.7	32
94	Antineutrophil cytoplasmic antibody-associated glomerulonephritis in Taiwanese. <i>Nephrology</i> , 2004, 9, 297-303.	0.7	4
95	Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. <i>American Journal of Kidney Diseases</i> , 2004, 43, 1047-1055.	2.1	95
96	Tumor necrosis factor- α stimulates fractalkine production by mesangial cells and regulates monocyte transmigration: Down-regulation by cAMP. <i>Kidney International</i> , 2003, 63, 474-486.	2.6	29
97	Antibiotics induce apoptosis of human peritoneal mesothelial cells. <i>Nephrology</i> , 2003, 8, 142-149.	0.7	15
98	Inhibition by pentoxifylline of TNF- α -stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF- κ B down-regulation. <i>British Journal of Pharmacology</i> , 2003, 138, 950-958.	2.7	45
99	Pentoxifylline Inhibits Platelet-Derived Growth Factor-Stimulated Cyclin D1 Expression in Mesangial Cells by Blocking Akt Membrane Translocation. <i>Molecular Pharmacology</i> , 2003, 64, 811-822.	1.0	34
100	Pentoxifylline modulates intracellular signalling of TGF- β in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 670-676.	0.4	44
101	Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-Thy1 glomerulonephritis in rats. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2505-2514.	0.4	24
102	Influence of Relative Hypoparathyroidism on the Responsiveness to Recombinant Human Erythropoietin in Hemodialysis Patients. <i>Blood Purification</i> , 2003, 21, 220-224.	0.9	6
103	Effects of Pentoxifylline on Peritoneal Fibroblasts and Silica-Induced Peritoneal Fibrosis. <i>Peritoneal Dialysis International</i> , 2003, 23, 228-236.	1.1	21
104	Effects of pentoxifylline on peritoneal fibroblasts and silica-induced peritoneal fibrosis. <i>Peritoneal Dialysis International</i> , 2003, 23, 228-36.	1.1	10
105	Pentoxifylline Attenuated the Renal Disease Progression in Rats with Remnant Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2916-2929.	3.0	106
106	Association between serum aspartate transaminase and homocysteine levels in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1195-1201.	2.1	16
107	Peritoneal fibrosis and its prevention. <i>Nephrology</i> , 2002, 7, 227-232.	0.7	7
108	Cardiopulmonary resuscitation in dialysis patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2002, 6, 160-162.	0.9	1

#	ARTICLE	IF	CITATIONS
109	Systemic Lupus Erythematosus and Peritoneal Dialysis: Outcomes and Infectious Complications. <i>Peritoneal Dialysis International</i> , 2001, 21, 143-148.	1.1	35
110	Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. <i>Kidney International</i> , 2001, 59, 2316-2324.	2.6	22
111	Dipyridamole inhibits TGF- β -induced collagen gene expression in human peritoneal mesothelial cells. <i>Kidney International</i> , 2001, 60, 1249-1257.	2.6	49
112	Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. <i>Kidney International</i> , 2001, 60, 872-881.	2.6	24
113	Chronic Fatigue in Long-Term Peritoneal Dialysis Patients. <i>American Journal of Nephrology</i> , 2001, 21, 479-485.	1.4	44
114	Pentoxifylline inhibits human peritoneal mesothelial cell growth and collagen synthesis: Effects on TGF- β . <i>Kidney International</i> , 2000, 57, 2626-2633.	2.6	44
115	Natural Changes in Peritoneal Equilibration Test Results in Continuous Ambulatory Peritoneal Dialysis Patients: A Retrospective, Seven Year Cohort Survey. <i>Artificial Organs</i> , 2000, 24, 261-264.	1.0	23
116	Relationship between Dialysis Adequacy and Quality of Life in Long-Term Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2000, 20, 534-540.	1.1	31
117	Surgical Management of Refractory Exit-Site/Tunnel Infection of Tenckhoff Catheter: Technical Innovations of Partial Replantation. <i>Peritoneal Dialysis International</i> , 1999, 19, 451-454.	1.1	34
118	Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. <i>Kidney International</i> , 1999, 56, 932-943.	2.6	74
119	Pentoxifylline Inhibits PDGF-induced Proliferation of and TGF- β -stimulated Collagen Synthesis by Vascular Smooth Muscle Cells. <i>Journal of Molecular and Cellular Cardiology</i> , 1999, 31, 773-783.	0.9	52
120	Impact of Peritoneal Membrane Transport on Technique Failure and Patient Survival in a Population on Automated Peritoneal Dialysis. <i>ASAIO Journal</i> , 1999, 45, 568-573.	0.9	36
121	Clinical Findings and Outcomes of Intra-Hemodialysis Cardiopulmonary Resuscitation. <i>American Journal of Nephrology</i> , 1999, 19, 468-473.	1.4	30
122	Viral Hepatitis Infection Should Be Considered for Evaluating Uremic Pruritus in Continuous Ambulatory Peritoneal Dialysis Patients. <i>Blood Purification</i> , 1998, 16, 147-153.	0.9	16
123	Viral Hepatitis in Continuous Ambulatory Peritoneal Dialysis Patients in an Endemic Area for Hepatitis B and C Infection: The Taiwan Experience. <i>Blood Purification</i> , 1997, 15, 195-199.	0.9	17
124	Extracellular Matrix Proteins Modulate Human Peritoneal Mesothelial Cell Behavior. <i>Nephron</i> , 1997, 75, 188-195.	0.6	13
125	Fibroadhesive Form of Tuberculous Peritonitis: Chyloperitoneum in a Patient Undergoing Automated Peritoneal Dialysis. <i>Nephron</i> , 1996, 72, 708-711.	0.9	17
126	Effects of Intraperitoneal Antibiotics on Human Peritoneal Mesothelial Cell Growth. <i>Nephron</i> , 1996, 74, 694-700.	0.6	13

#	ARTICLE	IF	CITATIONS
127	RENAL KALLIKREIN IN CHRONIC HYPOXIC RATS. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 819-824.	0.9	8
128	Disintegrin Modulates Rat Glomerular Mesangial Cell Behavior. Nephron, 1995, 70, 83-90.	0.9	11
129	Vasodilator Agents Modulate Rat Glomerular Mesangial Cell Growth and Collagen Synthesis. Nephron, 1995, 70, 91-99.	0.9	52
130	Effect of Intraperitoneally Administered Agents on Human Peritoneal Mesothelial Cell Growth. Nephron, 1995, 71, 23-28.	0.9	21